Drugs Made In America Acquisition Corp. Rights (DMAAR) short interest & short volume · 0.2% of float short
Drugs Made In America Acquisition Corp. Rights official short interest (FINRA, twice monthly) and daily short volume (FINRA Reg SHO), with history, % of float and days to cover.
What changed
DMAAR short interest fell 6.0% to 57K shares in the Oct 15, 2026 report (0.2% of float, 7.2 days to cover). Daily short volume averaged 44.8% of volume over the last 20 sessions, down from 74.5% the 20 sessions before, the 28th percentile of its own 20-day averages since Sep 16, 2025.
Short interest
Official, twice monthly · settled Oct 15, 2026
- Shares short
- 57K
- prior 61K
- % of float
- 0.2%
- float 27.3M
- Days to cover
- 7.2
- avg vol 8K
- Change vs prior report
- -6.0%
Days to cover is short interest divided by FINRA's average daily volume for the period: how many average days of trading it would take shorts to buy back.
% of float uses the current float for every report (no float was stored with older reports).
Source: FINRA equity short interest (twice monthly) · Settlement Oct 15, 2026
Daily short volume
Share of each day's volume sold short · FINRA Reg SHO
- Latest (Oct 29)
- 5.8%
- 500 of 9K
- 20-day average
- 44.8%
- prior 74.5%
- Percentile vs own history
- 28th
- 158 periods since 2025
Loading prices…
Source: FINRA Reg SHO daily short sale volume · Latest Oct 29, 2026
Short squeeze score (model)
Price since settlement: -1.3%
Model, not a forecast: 40 pts short interest % of float (full at 30%), 25 pts days to cover (full at 10), 15 pts rise in short interest since the prior report (full at +50%), 20 pts price gain since the settlement date (full at +25%). Missing inputs score 0.
DMAAR's squeeze score and its inputs with Lician Pro.Start 3-day trial — $149/yr
Market-wide: most shorted stocks, biggest changes and unusual short volume · DMAAR overview
| Date | Short | Total | Short % of volume |
|---|---|---|---|
| 2026-10-29 | 500 | 8,623 | 5.8% |
| 2026-10-27 | 5,300 | 10,700 | 49.5% |
| 2026-10-26 | 200 | 204 | 98.0% |
| 2026-10-23 | 308 | 308 | 100.0% |
| 2026-10-20 | 1,500 | 2,600 | 57.7% |
| 2026-10-15 | 13,160 | 17,460 | 75.4% |
| 2026-10-14 | 2,600 | 9,666 | 26.9% |
| 2026-10-12 | 200 | 1,200 | 16.7% |
| 2026-10-08 | 1,166 | 2,634 | 44.3% |
| 2026-10-06 | 424 | 10,900 | 3.9% |
DMAAR short interest FAQ
What is DMAAR's short interest?
Drugs Made In America Acquisition Corp. Rights (DMAAR) had 57K shares sold short and not yet covered in FINRA's Oct 15, 2026 settlement report, 0.2% of its 27.3M-share float.
How many days to cover does DMAAR have?
7.2 days: 57K shares short divided by an average daily volume of 8K for the Oct 15, 2026 period.
Is DMAAR short interest rising or falling?
DMAAR short interest fell (-6.0%) from 61K to 57K shares in the Oct 15, 2026 report.
Is DMAAR a short squeeze candidate?
Lician's squeeze watch scores DMAAR 18 out of 100 (low) from the Oct 15, 2026 report: short interest % of float 0.3/40, days to cover 18/25, change in short interest vs prior report 0/15, price change since settlement date 0/20. It is a transparent model of how crowded the short side is, not a forecast that a squeeze will happen.
What share of DMAAR daily volume is sold short?
44.8% on average over the last 20 sessions to Oct 29, 2026 (FINRA Reg SHO daily short volume; the 28th percentile of its own 20-day averages). Short volume counts market makers' same-day short sales, so it is not short interest.
What was DMAAR's latest FINRA short volume?
On Oct 29, 2026, cached FINRA short volume for Drugs Made In America Acquisition Corp. Rights (DMAAR) was 500 shares, 5.8% of 8,623 total volume.
How many DMAAR short-volume sessions are listed on this page?
This page lists 10 cached FINRA short-volume sessions for Drugs Made In America Acquisition Corp. Rights (DMAAR), from Oct 6, 2026 through Oct 29, 2026.
How did DMAAR short volume percent change from the prior cached session?
Cached FINRA short volume for Drugs Made In America Acquisition Corp. Rights (DMAAR) moved from 49.5% on Oct 27, 2026 to 5.8% on Oct 29, 2026, down 43.7 percentage points.
Not investment advice. Figures as filed or reported, not a live feed.